FDA Vote Sets Stage for Gene Therapy’s Future

Thursday, October 12, 2017

An independent committee of experts voted 16-0 in a unanimous recommendation that the U.S. Food and Drug Administration approve the treatment, called Luxturna and made by Philadelphia-based Spark Therapeutics. If approved, Luxturna would be the first treatment in the U.S. meant to fix an inherited genetic trait. The FDA must decide by January 12 whether to give it the green light. Chief research officer of the Foundation Fighting Blindness, Steve Rose, was interviewed by MIT Technology Review to share his expertise on the therapy. Read more about this pioneering treatment here.